The role of postoperative radiotherapy in hepatocellular carcinoma

Lee, Joongyo; Seong, Jinsil

doi:10.21037/hbsn-21-500

Search citation statements

Order By: Relevance

Paper Sections

Select...

Adjuvant Therapy After Conversion Surgery1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Surgeons try to ensure that there will be enough residual liver in the future to avoid liver failure after resection, which leads to narrow margins. It is frequently associated with marginal recurrence [45]. A phase 2 clinical study suggests that intensity-modulated radiotherapy (IMRT) may improve disease-free survival (DFS) in patients undergoing narrow-margin hepatectomy [46].…”

Section: Adjuvant Therapy After Conversion Surgerymentioning

confidence: 99%

From Conversion to Resection for Unresectable Hepatocellular Carcinoma: A Review of the Latest Strategies

Liang,

He,

Tao

et al. 2023

JCM

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in China, accounting for the majority of primary liver cancer cases. Liver resection is the preferred curative method for early-stage HCC. However, up to 80–85% of patients have already missed the opportunity of radical surgery due to tumor advances at the time of consultation. Conversion therapies are a series of medications and treatments for initially inoperable patients. For early-stage unresectable HCC (uHCC) patients, conversion therapies are designed to meet surgical requirements by increasing the volume of the residual liver. Meanwhile, for advanced cases, conversion therapies strive for tumor shrinkage and down-staging, creating the opportunity for liver resection or liver transplantation. This review summarizes the latest advances in conversion therapies and highlights their potential for improving the survival benefit of patients with uHCC.

show abstract

Section: Adjuvant Therapy After Conversion Surgerymentioning

confidence: 99%